342 related articles for article (PubMed ID: 33607404)
1. Siglec and anti-Siglec therapies.
Murugesan G; Weigle B; Crocker PR
Curr Opin Chem Biol; 2021 Jun; 62():34-42. PubMed ID: 33607404
[TBL] [Abstract][Full Text] [Related]
2. Sialic Acid-Siglec Axis in Human Immune Regulation, Involvement in Autoimmunity and Cancer and Potential Therapeutic Treatments.
Gianchecchi E; Arena A; Fierabracci A
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071314
[TBL] [Abstract][Full Text] [Related]
3. Tools to study and target the Siglec-sialic acid axis in cancer.
Läubli H; Kawanishi K; George Vazhappilly C; Matar R; Merheb M; Sarwar Siddiqui S
FEBS J; 2021 Nov; 288(21):6206-6225. PubMed ID: 33251699
[TBL] [Abstract][Full Text] [Related]
4. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
Adams OJ; Stanczak MA; von Gunten S; Läubli H
Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
[TBL] [Abstract][Full Text] [Related]
5. Modulation of Immune Tolerance via Siglec-Sialic Acid Interactions.
Lübbers J; Rodríguez E; van Kooyk Y
Front Immunol; 2018; 9():2807. PubMed ID: 30581432
[TBL] [Abstract][Full Text] [Related]
6. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
Bärenwaldt A; Läubli H
Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
[No Abstract] [Full Text] [Related]
7. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
Daly J; Carlsten M; O'Dwyer M
Front Immunol; 2019; 10():1047. PubMed ID: 31143186
[TBL] [Abstract][Full Text] [Related]
8. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
9. Roles of the Siglec family in bone and bone homeostasis.
Ye Z; Wang Y; Xiang B; Wang H; Tao H; Zhang C; Zhang S; Sun D; Luo F; Song L
Biomed Pharmacother; 2023 Sep; 165():115064. PubMed ID: 37413904
[TBL] [Abstract][Full Text] [Related]
10. Sialoglycans and Siglecs Can Shape the Tumor Immune Microenvironment.
van de Wall S; Santegoets KCM; van Houtum EJH; Büll C; Adema GJ
Trends Immunol; 2020 Apr; 41(4):274-285. PubMed ID: 32139317
[TBL] [Abstract][Full Text] [Related]
11. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
12. Viewing Siglecs through the lens of tumor immunology.
Fraschilla I; Pillai S
Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
[TBL] [Abstract][Full Text] [Related]
13. Sialic Acid Mimetics to Target the Sialic Acid-Siglec Axis.
Büll C; Heise T; Adema GJ; Boltje TJ
Trends Biochem Sci; 2016 Jun; 41(6):519-531. PubMed ID: 27085506
[TBL] [Abstract][Full Text] [Related]
14. B Cell Siglecs-News on Signaling and Its Interplay With Ligand Binding.
Meyer SJ; Linder AT; Brandl C; Nitschke L
Front Immunol; 2018; 9():2820. PubMed ID: 30559744
[TBL] [Abstract][Full Text] [Related]
15. Possible Influences of Endogenous and Exogenous Ligands on the Evolution of Human Siglecs.
Angata T
Front Immunol; 2018; 9():2885. PubMed ID: 30564250
[TBL] [Abstract][Full Text] [Related]
16. Siglecs in Brain Function and Neurological Disorders.
Siddiqui SS; Matar R; Merheb M; Hodeify R; Vazhappilly CG; Marton J; Shamsuddin SA; Al Zouabi H
Cells; 2019 Sep; 8(10):. PubMed ID: 31546700
[TBL] [Abstract][Full Text] [Related]
17. Assessment of sialic acid diversity in cancer- and non-cancer related CA125 antigen using sialic acid-binding Ig-like lectins (Siglecs).
Mitic N; Milutinovic B; Jankovic M
Dis Markers; 2012; 32(3):187-94. PubMed ID: 22377735
[TBL] [Abstract][Full Text] [Related]
18. Impact of Siglecs on autoimmune diseases.
Brzezicka KA; Paulson JC
Mol Aspects Med; 2023 Apr; 90():101140. PubMed ID: 36055802
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Siglec-Sialic Acid Immune Axis in Cancer: Current and Future Approaches.
Läubli H; Nalle SC; Maslyar D
Cancer Immunol Res; 2022 Dec; 10(12):1423-1432. PubMed ID: 36264237
[TBL] [Abstract][Full Text] [Related]
20. Current Status on Therapeutic Molecules Targeting Siglec Receptors.
Lenza MP; Atxabal U; Oyenarte I; Jiménez-Barbero J; Ereño-Orbea J
Cells; 2020 Dec; 9(12):. PubMed ID: 33333862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
